NEW YORK, NY / ACCESS Newswire / February 13, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has bee ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

The trial showed that patients treated with CagriSema exhibited weight loss of 22.7% after 68 weeks, well short of Novo's targeted expectation of at least 25% weight loss. The press release ...

(Bloomberg) -- Novo Nordisk A/S investors got a much-needed ... coming after disappointing results for a separate drug called CagriSema in December. The experimental CagriSema shot missed Novo ...

(Bloomberg) -- Novo Nordisk A/S investors got a much-needed boost from last ... with a chunk of the drop coming after disappointing results for a separate drug called CagriSema in December. The ...

NEW YORK, Jan. 30, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE ... investigating subcutaneous CagriSema." The trial showed ...

LONDON, Jan 30 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab will begin a late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10 to test its long-term efficacy ...

LONDON, Jan 30 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Thursday it has not yet posted details about a new trial of its experimental next-generation obesity drug CagriSema ...

However, not all news has been positive. Novo Nordisk faced setbacks with its CagriSema obesity treatment, as the results from the REDEFINE-1 trial were disappointing, showing lower-than-expected ...